Abstract |
AbobotulinumtoxinA (aboBoNT-A; Dysport®) is an effective treatment for cervical dystonia (CD) with a well-established safety profile. In this prospective, multicentre, non-interventional study (NCT01840462) the primary objective was effectiveness (Tsui score) of aboBoNT-A in botulinum neurotoxin type A ( BoNT-A) treatment-naïve and previously-treated (>2 yrs) patients after two injection cycles (at visit 3). Secondary objectives included the effectiveness of aboBoNT-A overall visits and quality of life (CDQ-24) in different CD subtypes. Observation time was 12-16 months, including 5 visits and 4 injection cycles (each 3-4 months). In the analysis population 273 patients from 41 centres across Germany and Austria were included. At baseline, 62.6% were previously-treated with BoNT-A. The major primary components of CD were torticollis (64.5%) and torticaput (17.6%). Previously-treated patients showed a slight reduction of the Tsui scores, whereas BoNT-A-naïve patients had a more severe baseline Tsui score and improved much more over all cycles. Results were similar for CDQ-24. Interestingly, improvements mainly occurred in the Tsui subscore A (amplitude of sustained posture). Marked differences between CD subtypes regarding effectiveness could not be determined. To our knowledge this is the first large multi-centre study investigating the effectiveness of BoNT-A in different primary subtypes of CD over several injection cycles.
|
Authors | W H Jost, A Schramm, M Müngersdorf, A Stenner, P Schwingenschuh, P Maisonobe, M Koch, B Haslinger |
Journal | Journal of the neurological sciences
(J Neurol Sci)
Vol. 399
Pg. 44-50
(Apr 15 2019)
ISSN: 1878-5883 [Electronic] Netherlands |
PMID | 30771702
(Publication Type: Journal Article)
|
Copyright | Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved. |
Chemical References |
- Acetylcholine Release Inhibitors
- Botulinum Toxins, Type A
- abobotulinumtoxinA
|
Topics |
- Acetylcholine Release Inhibitors
(therapeutic use)
- Adult
- Aged
- Aged, 80 and over
- Austria
- Botulinum Toxins, Type A
(therapeutic use)
- Female
- Germany
- Humans
- Male
- Middle Aged
- Product Surveillance, Postmarketing
- Prospective Studies
- Quality of Life
- Torticollis
(drug therapy)
- Treatment Outcome
- Young Adult
|